Squamosamide derivative FLZ protected dopaminergic neuron by activating Akt signaling pathway in 6-OHDA-induced in vivo and in vitro Parkinson's disease models
- 1 February 2014
- journal article
- Published by Elsevier in Brain Research
- Vol. 1547, 49-57
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81000568, 81001430)
- Chinese National Basic Research Program (2011CB504105)
- Beijing Nova Program (Z111102054511129)
- Beijing City Talents (2012D009008000005)
- Fundamental Research Funds for the Central Universities (2012S08)
- PUMC Youth Fund (2012J19, 3332013111, 3332013128)
This publication has 25 references indexed in Scilit:
- FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson's disease modelsNeuroscience, 2012
- Age and α-synuclein expression interact to reveal a dependence of dopaminergic axons on endogenous Akt/PKB signalingNeurobiology of Disease, 2011
- Direct Interaction of α-Synuclein and AKT Regulates IGF-1 Signaling: Implication of Parkinson DiseaseNeurosignals, 2011
- Rescue of α-synuclein cytotoxicity by insulin-like growth factorsBiochemical and Biophysical Research Communications, 2009
- The 6-hydroxydopamine model: News from the pastParkinsonism & Related Disorders, 2008
- The Akt–GSK-3 signaling cascade in the actions of dopamineTrends in Pharmacological Sciences, 2007
- Molecular pathogenesis of Parkinson's diseaseHuman Molecular Genetics, 2005
- Akt Is Essential for Insulin Modulation of Amphetamine-Induced Human Dopamine Transporter Cell-Surface RedistributionMolecular Pharmacology, 2005
- Retrograde propagation of GDNF-mediated signals in sympathetic neuronsMolecular and Cellular Neuroscience, 2004
- Parkinson's DiseaseNeuron, 2003